Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?

Published by
Kaiser Health News

The approval of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment — problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal aging. After initially indicating that Aduhelm could be prescribed to anyone with dementia, the Food and Drug Administration now specifies that the prescription drug be given to individuals with mild cognitive impairment or early-stage Alzheimer’s, the groups in which the medication was studied. Yet this narrower recommendation raises questions. What does a dia…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *